menu
    • menu

    Company profile for BioSkryb

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BioSkryb has ushered in a whole new era of single-cell whole genome amplification. The benefits of the BioSkryb ResolveDNA™ technology include the ability to control the amplicon size during amplification. This allows the incorporation of barcode identifiers into each sample template, enabling unparalleled reproducibility and sensitive detection of DNA lesions. Our complete workflow solution is especially useful in cancer re...
    BioSkryb has ushered in a whole new era of single-cell whole genome amplification. The benefits of the BioSkryb ResolveDNA™ technology include the ability to control the amplicon size during amplification. This allows the incorporation of barcode identifiers into each sample template, enabling unparalleled reproducibility and sensitive detection of DNA lesions. Our complete workflow solution is especially useful in cancer research as it allows the detection of single resistant mutant cells (MRD) in heterogeneous cancers such as leukemia. BioSkryb’s leadership team has decades of combined scientific and management experience.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BioSkrybUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    701 W Main St, Suite 200 Durham, NC 27701
    Telephone
    Telephone
    919-370-0841
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bioskryb.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bioskryb Genomics Launches Resolveseq Longread Early Access
    Bioskryb Genomics Launches Resolveseq Longread Early Access

    07 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251007896386/en/BioSkryb-Genomics-Launches-ResolveSEQ-LongRead-Early-Access-Program-for-Powerful-Single-Cell-Long-Read-Sequencing

    BUSINESSWIRE
    07 Oct 2025
    Share Share
    BioSkryb Secures License for Single-Cell Five-Base Genome Patent
    BioSkryb Secures License for Single-Cell Five-Base Genome Patent

    20 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250820660089/en/BioSkryb-Genomics-Secures-Exclusive-License-to-Breakthrough-Methylation-Patent-to-Enable-the-First-Single-Cell-Five-Base-Genome

    BUSINESSWIRE
    20 Aug 2025
    Share Share
    BioSkryb Genomics and Tecan launch single-cell multiomics workflow
    BioSkryb Genomics and Tecan launch single-cell multiomics workflow

    25 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250425089956/en/BioSkryb-Genomics-and-Tecan-introduce-a-single-cell-multiomics-workflow-for-sequencing-ready-libraries-in-under-ten-hours

    BUSINESSWIRE
    25 Apr 2025
    Share Share
    BioSkryb, Ultima Grant to Boost Oncology Research
    BioSkryb, Ultima Grant to Boost Oncology Research

    23 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250423546334/en/BioSkryb-Genomics-and-Ultima-Genomics-Launch-Collaborative-Grant-Program-to-Advance-Oncology-Research

    BUSINESSWIRE
    23 Apr 2025
    Share Share
    BioSkryb Genomics Launches ResolveSEQ MRD Discovery Solution
    BioSkryb Genomics Launches ResolveSEQ MRD Discovery Solution

    08 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250108129909/en

    BUSINESSWIRE
    08 Jan 2025
    Share Share
    BioXpedia A/S and BioSkryb Genomics Announce European Partnership
    BioXpedia A/S and BioSkryb Genomics Announce European Partnership

    21 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220920005474/en

    BUSINESSWIRE
    21 Sep 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search